Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Changes in glitazone use among office-based physicians in the U.S., 2003-2009.

Cohen A, Rabbani A, Shah N, Alexander GC.

Diabetes Care. 2010 Apr;33(4):823-5. doi: 10.2337/dc09-1834. Epub 2010 Jan 26.

2.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

3.

Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.

Ahuja V, Sohn MW, Birge JR, Syverson C, Budiman-Mak E, Emanuele N, Cooper JM, Huang ES.

J Manag Care Spec Pharm. 2015 Dec;21(12):1214-34.

4.

Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.

Hall GC, Smith HT, Curtis B, McMahon AD.

Int J Clin Pract. 2011 May;65(5):586-91. doi: 10.1111/j.1742-1241.2011.02648.x.

PMID:
21489082
5.

Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.

Niyomnaitham S, Page A, La Caze A, Whitfield K, Smith AJ.

BMC Health Serv Res. 2014 Apr 4;14:151. doi: 10.1186/1472-6963-14-151.

6.

Use of cholesterol-lowering medications in the United States from 1991 to 1997.

Siegel D, Lopez J, Meier J.

Am J Med. 2000 Apr 15;108(6):496-9. No abstract available.

PMID:
10781783
7.

Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.

Kornfield R, Watson S, Higashi AS, Conti RM, Dusetzina SB, Garfield CF, Dorsey ER, Huskamp HA, Alexander GC.

Psychiatr Serv. 2013 Apr 1;64(4):339-46. doi: 10.1176/appi.ps.201200147.

8.

Rosiglitazone and cardiovascular risk.

Brett AS.

N Engl J Med. 2007 Aug 30;357(9):939; author reply 939-40. No abstract available.

PMID:
17806134
9.

Physician prescribing rates climb.

[No authors listed]

Manag Care. 2002 Sep;11(9):56. No abstract available.

10.

The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus.

Lub R, Denig P, van den Berg PB, Hoogenberg K, de Jong-van den Berg LT.

Br J Clin Pharmacol. 2006 Dec;62(6):660-5. Epub 2006 Jun 23.

11.

National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Hersh AL, Stefanick ML, Stafford RS.

JAMA. 2004 Jan 7;291(1):47-53.

PMID:
14709575
12.

Thiazolidinedione use in elderly patients with type 2 diabetes: with and without heart failure.

Seong JM, Choi NK, Jung SY, Chang Y, Kim YJ, Lee J, Park BJ.

Pharmacoepidemiol Drug Saf. 2011 Apr;20(4):344-50. doi: 10.1002/pds.2112. Epub 2011 Feb 17.

PMID:
21328632
13.

How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

Hsu JC, Ross-Degnan D, Wagner AK, Zhang F, Lu CY.

Clin Ther. 2015 Jul 1;37(7):1420-1432.e1. doi: 10.1016/j.clinthera.2015.04.006. Epub 2015 May 11.

14.

Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.

Ruiter R, Visser LE, van Herk-Sukel MP, Geelhoed-Duijvestijn PH, de Bie S, Straus SM, Mol PG, Romio SA, Herings RM, Stricker BH.

Drug Saf. 2012 Jun 1;35(6):471-80. doi: 10.2165/11596950-000000000-00000.

PMID:
22540371
15.
16.

Physicians' prescribing patterns for patients with diabetes are changing for the better.

Rodbard HW, Jellinger PS.

Am J Med. 2012 Nov;125(11):e11-2. doi: 10.1016/j.amjmed.2012.04.035. No abstract available.

PMID:
23098867
17.

Insulin therapy: evolution and practice.

Hirsch IB.

Endocrinol Metab Clin North Am. 2007 Dec;36 Suppl 2:7-8. No abstract available.

PMID:
18407029
18.

Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone.

Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifirò G.

Br J Clin Pharmacol. 2013 Mar;75(3):861-8. doi: 10.1111/j.1365-2125.2012.04401.x.

19.

Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.

Balkrishnan R, Arondekar BV, Camacho FT, Shenolikar RA, Horblyuk R, Anderson RT.

Clin Ther. 2007 Jun;29(6 Pt 1):1306-15.

PMID:
18036392
20.

Increasing off-label use of antipsychotic medications in the United States, 1995-2008.

Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS.

Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):177-84. doi: 10.1002/pds.2082. Epub 2011 Jan 6.

Supplemental Content

Support Center